We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > navicixizumab

News List

QIAGEN and OncXerna Therapeutics Sign Licensing and Master Companion Diagnostic Agreements firstwordpharma
August 10, 2021
QIAGEN and OncXerna Therapeutics, Inc. today announced signing a master companion diagnostics (CDx) agreement to develop a NGS CDx for OncXerna's product candidate, Navicixizumab, and a non-exclusive license to the Xerna™ TME panel.
Celgene walks away from Oncomed’s navicixizumab pharmatimes
September 27, 2018
Celgene has decided not to exercise its option to license OncoMed's bispecific antibody navicixizumab.
Celgene walks away from Oncomed’s navicixizumab pharmatimes
September 21, 2018
Celgene has decided not to exercise its option to license OncoMed's bispecific antibody navicixizumab.